Leaked IPR Draft Revives India’s Data Protection Bogey?
This article was originally published in PharmAsia News
A leaked final draft of India's national intellectual property rights (IPR) policy suggests creating an "appropriate framework" for protection of undisclosed information submitted in the drug approval process, though it does not endorse data exclusivity.
You may also be interested in...
Scrip traces some of the prominent changes in the corner office at front-line, family-owned Indian firms Cipla and Dr Reddy’s in the decade gone by.
Glenmark has struck a deal with private equity firm True North for its gynecology business in India and Nepal.
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.